小细胞肺癌治疗市场－全球产业规模、份额、趋势、机会及预测（依治疗类型、药物类型、通路、地区及竞争格局划分，2021-2031年）

全球小细胞肺癌治疗市场预计将从 2025 年的 69.1 亿美元大幅成长至 2031 年的 127.5 亿美元，复合年增长率达 10.75%。

该领域专注于研发和商业化药物干预措施，包括化疗、免疫疗法和标靶药物，旨在对抗这种侵袭性神经内分泌癌症。推动这一增长的关键因素包括全球吸烟率上升和人口老化，这两者都导致急需治疗的患者群体不断扩大。此外，免疫查核点抑制剂的频繁核准正在重新定义治疗标准，也推动了市场的发展。国际癌症研究机构 (IARC) 的数据显示，在最新的报告期间内，2025 年全球新增小细胞肺癌病例将约占 26.8 万例。

儘管市场有所成长，但仍面临许多障碍，包括先进免疫疗法的高成本，这限制了医疗预算有限的开发中国家患者获得治疗的机会。严格的报销政策和医疗系统沉重的财政负担往往阻碍了这些现代治疗方法的广泛应用，导致主要新兴市场的收入成长停滞不前。因此，儘管临床对有效治疗方法的需求依然旺盛，但经济障碍仍阻碍着这些治疗创新成果的全面商业性化。

市场驱动因素

先进免疫疗法和标靶药物的引入和广泛应用正在从根本上改变小细胞肺癌的治疗模式。监管机构正越来越多地核准针对特定生物路径的创新治疗方法，为那些病情已超出标准化疗的患者提供新的治疗选择。这种变化的显着体现是靶向Delta样配体3的双特异性T细胞衔接器的出现，这标誌着治疗模式与传统模式的重大转变。例如，安进公司在2024年5月的新闻稿中宣布，FDA已加速核准IMDELLTRA（tallatamab-dlle）用于治疗晚期小细胞肺癌。此核准是基于临床试验结果，结果显示IMDELLTRA在晚期患者中的中位缓解持续时间为9.7个月，这一突破性成果揭示了一种全新的作用机制，并将促进其在临床上的进一步应用。

与这些监管方面的成就一致，市场正受到旨在拓展肿瘤产品组合的大规模企业投资和策略性收购的推动。製药公司正积极寻求併购，以确保获得前景广阔的在研疗法，特别是那些利用免疫活化和精准肿瘤标靶化技术的疗法。正如默克在2024年1月的新闻稿中所宣布的，该公司同意以约6.8亿美元的价格收购Harpoon Therapeutics，以将新型T细胞衔接器纳入其开发平臺。这些策略性财务措施将稳定研发资金，并加速临床试验到产品上市的进程。此外，美国癌症协会指出，到2024年，小细胞肺癌将占所有肺癌病例的10%至15%左右，凸显了持续治疗方法创新的迫切性。

市场挑战

新型免疫疗法的高昂价格是全球小细胞肺癌治疗市场的主要阻碍因素。这些高成本构成了广泛应用的重大经济障碍，尤其是在医疗资金有限的地区。面对预算限制，各国医疗体系和支付者往往实施严格的报销通讯协定，导致病患无法获得昂贵的治疗。因此，医疗服务提供者常常被迫使用老旧的非专利化疗药物，而非先进的疗法，这直接限制了价格敏感地区製药企业的商机。

近期产业数据显示，患者负担能力问题凸显了这项经济负担的影响。根据美国癌症协会（ACS）发布的《2024年报告》，约58%的癌症患者面临与治疗费用和保险自付部分相关的经济困难。这种经济压力限制了能够负担这些昂贵治疗的患者数量，从而显着缩小了整体市场规模。最终，临床需求与较佳治疗方法的经济可行性之间的差距，持续阻碍这些疗法的商业性发展。

市场趋势

免疫疗法联合治疗作为标准治疗方案的应用范围正从晚期疾病扩展到包括局限期小细胞肺癌，从而为早期疗育创造了新的治疗模式。这一趋势是将免疫查核点抑制剂与放射线治疗合併使用，以提高潜在可治癒患者的存活率。 2024年6月，Astra Zeneca在ASCO会议上公布了其III期ADRIATIC试验的结果，结果显示，在放射线治疗后病情未进展的局限期患者中，Durvalumab与安慰剂相比，死亡风险降低了27%。免疫疗法适应症的扩展标誌着该市场的一个重要转折点，为近几十年来鲜有治疗突破的患者群体确立了新的治疗标准。

同时，针对 DLL3 的抗体药物复合体(ADC) 的兴起，正在建立一种与双特异性 T 细胞衔接器作用机制不同的强效细胞毒性治疗方法。与活化免疫系统的治疗方法不同，这些偶联物利用特异性抗体将化疗直接递送至表达Delta的癌细胞，从而有效避免了全身化疗中常见的抗药性问题。 2024 年 9 月，第一三共株式会社公布了 II 期临床试验「IDeate-Lung01」的中期分析结果，报告显示，伊菲那他单抗德鲁替康在 12 mg/kg 剂量组中的确认客观缓解率达到 54.8%。这项进展表明，抗体药物复合体作为一种精准标靶治疗策略，在先前接受过治疗的晚期疾病治疗中具有越来越高的可行性。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球小细胞肺癌药物市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依治疗方法（免疫疗法、标靶治疗、化疗）
  • 依药物类型（Atezolizumab、拓朴替康、鲁比替定、度伐Durvalumab、胺基甲基叶酸呤製剂、Pembrolizumab）
  • 按分销管道（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美小细胞肺癌药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲小细胞肺癌药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区小细胞肺癌药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲小细胞肺癌药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美小细胞肺癌药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球小细胞肺癌药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Merck & Co., Inc.
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Eli Lilly and Company
• Aurobindo Pharma Limited
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Small Cell Lung Cancer Therapeutics Market is projected to expand significantly, rising from USD 6.91 Billion in 2025 to USD 12.75 Billion by 2031, reflecting a compound annual growth rate of 10.75%. This sector focuses on the creation and sale of pharmaceutical interventions, including chemotherapy, immunotherapies, and targeted agents designed to combat this aggressive neuroendocrine cancer. Key factors propelling this growth include the increasing global prevalence of tobacco use and an aging population, both of which contribute to a larger patient pool requiring immediate care. Additionally, the market is bolstered by frequent regulatory approvals for immune checkpoint inhibitors that are redefining treatment standards. Data from the International Agency for Research on Cancer indicates that in 2025, small-cell carcinoma was responsible for roughly 268,000 new lung cancer cases worldwide during the latest reporting period.

Despite this growth, the market faces significant hurdles due to the high costs of advanced immunotherapeutic regimens, which restrict patient access in developing nations with limited healthcare budgets. Strict reimbursement policies and the substantial financial strain on healthcare systems frequently hinder the widespread uptake of these modern therapies, subsequently stalling revenue progress in critical emerging markets. As a result, although clinical demand for effective treatments remains strong, economic obstacles continue to impede the full commercial realization of these therapeutic innovations.

Market Driver

The introduction and uptake of advanced immunotherapies and targeted agents are fundamentally transforming the treatment framework for small cell lung cancer. Regulatory bodies are increasingly authorizing innovative therapies that focus on specific biological pathways, providing renewed options for patients who have progressed past standard chemotherapy. This evolution is highlighted by the emergence of bispecific T-cell engagers targeting Delta-like ligand 3, representing a major shift from traditional care models. For instance, Amgen reported in a May 2024 press release that the FDA granted accelerated approval to IMDELLTRA (tarlatamab-dlle) following clinical trials that showed a median response duration of 9.7 months in patients with extensive-stage disease, a milestone that validates new mechanisms of action and spurs further clinical adoption.

In parallel with these regulatory achievements, the market is propelled by significant corporate investments and strategic acquisitions designed to broaden oncology portfolios. Pharmaceutical companies are actively engaging in mergers to secure promising investigational drugs, particularly those utilizing immune engagement and precise tumor targeting. As noted in a January 2024 press release, Merck agreed to acquire Harpoon Therapeutics for a total equity value of approximately $680 million to incorporate novel T-cell engagers into their development pipeline. These strategic financial actions ensure a steady flow of capital into research and development, speeding up the journey from clinical trials to the marketplace. Moreover, the American Cancer Society noted in 2024 that small cell lung cancer comprises about 10% to 15% of all lung cancer cases, emphasizing the urgent need for sustained therapeutic innovation.

Market Challenge

The steep prices attached to novel immunotherapeutic regimens serve as a major constraint on the Global Small Cell Lung Cancer Therapeutics Market. These high costs establish formidable economic hurdles that obstruct widespread adoption, especially in areas with restricted healthcare funding. Facing budgetary limitations, national health systems and payers often enforce rigorous reimbursement protocols that either delay or refuse access to costly treatments. Consequently, medical providers are frequently compelled to utilize older, generic chemotherapy alternatives instead of advanced agents, which directly limits potential revenue opportunities for pharmaceutical developers in price-sensitive regions.

The consequences of this financial toxicity are highlighted by recent industry data regarding patient affordability. According to the American Cancer Society's 2024 report, approximately 58 percent of cancer patients experienced financial difficulties related to treatment costs and insurance deductibles. This economic pressure restricts the number of patients able to afford high-value therapies, thereby significantly shrinking the overall market volume. Ultimately, the gap between the clinical necessity for better treatments and their economic feasibility continues to retard the commercial growth of these therapeutics.

Market Trends

The incorporation of immunotherapy combinations as a standard of care is extending beyond extensive-stage disease to include limited-stage small cell lung cancer, creating new treatment models for earlier intervention. This trend entails administering immune checkpoint inhibitors alongside concurrent chemoradiotherapy to enhance survival rates in patients with curative potential. In June 2024, AstraZeneca announced that results from the Phase III ADRIATIC trial presented at ASCO showed that durvalumab reduced the risk of death by 27% compared to placebo in patients with limited-stage disease who had not progressed after chemoradiotherapy. This broadening of immunotherapy indications marks a pivotal market shift, establishing a new care standard for a patient group that has experienced few therapeutic breakthroughs in recent decades.

Concurrently, the rise of DLL3-targeting antibody-drug conjugates is establishing a potent cytotoxic approach that functions differently from bispecific T-cell engagers. Unlike therapies that engage the immune system, these conjugates employ specific antibodies to transport chemotherapy payloads directly to tumor cells expressing Delta-like ligand 3, effectively bypassing resistance issues often seen with systemic chemotherapy. In September 2024, Daiichi Sankyo reported that an interim analysis of the Phase 2 IDeate-Lung01 trial showed ifinatamab deruxtecan achieved a confirmed objective response rate of 54.8% in patients receiving the 12 mg/kg dose. This progress highlights the increasing feasibility of antibody-drug conjugates as a precision-targeted strategy for treating pretreated extensive-stage disease.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Merck & Co., Inc.
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Eli Lilly and Company
• Aurobindo Pharma Limited
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.

Report Scope

In this report, the Global Small Cell Lung Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Small Cell Lung Cancer Therapeutics Market, By Therapy Type

• Immunotherapy
• Targeted Therapy
• Chemotherapy

Small Cell Lung Cancer Therapeutics Market, By Drug Type

• Atezolizumab
• Topotecan
• Lurbinectedin
• Durvalumab
• Methotrexate side
• Pembrolizumab

Small Cell Lung Cancer Therapeutics Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Small Cell Lung Cancer Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Small Cell Lung Cancer Therapeutics Market.

Available Customizations:

Global Small Cell Lung Cancer Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Small Cell Lung Cancer Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type (Immunotherapy, Targeted Therapy, Chemotherapy)
  • 5.2.2. By Drug Type (Atezolizumab, Topotecan, Lurbinectedin, Durvalumab, Methotrexate side, Pembrolizumab)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Small Cell Lung Cancer Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Drug Type
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Small Cell Lung Cancer Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Drug Type
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Small Cell Lung Cancer Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Drug Type
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Small Cell Lung Cancer Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Drug Type
      • 6.3.3.2.3. By Distribution Channel

7. Europe Small Cell Lung Cancer Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy Type
  • 7.2.2. By Drug Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Small Cell Lung Cancer Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Drug Type
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Small Cell Lung Cancer Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Drug Type
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Small Cell Lung Cancer Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Drug Type
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Small Cell Lung Cancer Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy Type
      • 7.3.4.2.2. By Drug Type
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Small Cell Lung Cancer Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy Type
      • 7.3.5.2.2. By Drug Type
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Small Cell Lung Cancer Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Drug Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Small Cell Lung Cancer Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Drug Type
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Small Cell Lung Cancer Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Drug Type
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Small Cell Lung Cancer Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Drug Type
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Small Cell Lung Cancer Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy Type
      • 8.3.4.2.2. By Drug Type
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Small Cell Lung Cancer Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy Type
      • 8.3.5.2.2. By Drug Type
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Small Cell Lung Cancer Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Small Cell Lung Cancer Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Drug Type
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Small Cell Lung Cancer Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Small Cell Lung Cancer Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Drug Type
      • 9.3.3.2.3. By Distribution Channel

10. South America Small Cell Lung Cancer Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy Type
  • 10.2.2. By Drug Type
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Small Cell Lung Cancer Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy Type
      • 10.3.1.2.2. By Drug Type
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Small Cell Lung Cancer Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy Type
      • 10.3.2.2.2. By Drug Type
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Small Cell Lung Cancer Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy Type
      • 10.3.3.2.2. By Drug Type
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Small Cell Lung Cancer Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Merck & Co., Inc.
• 15.4. Sun Pharmaceutical Industries Ltd.
• 15.5. Lupin Limited
• 15.6. Eli Lilly and Company
• 15.7. Aurobindo Pharma Limited
• 15.8. Bayer AG
• 15.9. Teva Pharmaceutical Industries Ltd.
• 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer